{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T09:25:50Z","timestamp":1793179550516,"version":"4.5.0"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,4]],"date-time":"2020-02-04T00:00:00Z","timestamp":1580774400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,2,4]],"date-time":"2020-02-04T00:00:00Z","timestamp":1580774400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Res Ther"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Despite advances in the treatment quality of HIV throughout the world, several countries are still facing numerous obstacles in delivering HIV treatment at a sufficiently high quality, putting patients\u2019 lives in jeopardy. The aim of this status article is to give an overview of HIV treatment outcomes in the West African country, Guinea-Bissau, and to assess how newer treatment strategies such as long-acting injectable drugs or an HIV cure may limit or stop the HIV epidemic in this politically unstable and low-resource setting. Several HIV cohorts in Guinea-Bissau have been established and are used as platforms for epidemiological, virological, immunological and clinical studies often with a special focus on HIV-2, which is prevalent in the country. The Bandim Health Project, a demographic surveillance site, has performed epidemiological HIV surveys since 1987 among an urban population in the capital Bissau. The Police cohort, an occupational cohort of police officers, has enabled analyses of persons seroconverting with estimated times of seroconversion among HIV-1 and HIV-2-infected individuals, allowing incidence measurements while the Bissau HIV Cohort and a newer Nationwide HIV Cohort have provided clinical data on large numbers of HIV-infected patients. The HIV cohorts in Guinea-Bissau are unique platforms for research and represent real life in many African countries. Poor adherence, lack of HIV viral load measurements, inadequate laboratory facilities, high rates of loss to follow-up, mortality, treatment failure and resistance development, are just some of the challenges faced putting the goal of \u201c90\u201390\u201390\u2033 for Guinea-Bissau well out of reach by 2020. Maintaining undetectable viral loads on treatment as a prerequisite of a cure strategy seems not possible at the moment. Thinking beyond one-pill-once-a-day, long-acting antiretroviral treatment options such as injectable drugs or implants may be a better treatment option in settings like Guinea-Bissau and may even pave the way for an HIV cure. If the delivery of antiretroviral treatment in sub-Saharan Africa in a sustainable way for the future should be improved by focusing on existing treatment options or through focusing on new treatment options remains to be determined.<\/jats:p>","DOI":"10.1186\/s12981-020-0259-6","type":"journal-article","created":{"date-parts":[[2020,2,4]],"date-time":"2020-02-04T11:03:17Z","timestamp":1580814197000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["HIV treatment in Guinea-Bissau: room for improvement and time for new treatment options"],"prefix":"10.1186","volume":"17","author":[{"given":"S.","family":"Jespersen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"M\u00e5nsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Lindman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Wejse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Medina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z. J.","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DdS","family":"Te","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Medstrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Esbj\u00f6rnsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. L.","family":"H\u00f8nge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,4]]},"reference":[{"issue":"12","key":"259_CR1","doi-asserted-by":"publisher","first-page":"909","DOI":"10.2471\/BLT.14.135749","volume":"92","author":"S Jespersen","year":"2014","unstructured":"Jespersen S, H\u00f8nge BL, Oliveira I, Medina C, da Silva Te D, Correia FG, et al. Challenges facing HIV treatment in Guinea-Bissau: the benefits of international research collaborations. Bull World Health Organ. 2014;92(12):909\u201314.","journal-title":"Bull World Health Organ"},{"issue":"3","key":"259_CR2","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1093\/ije\/dyu201","volume":"44","author":"S Jespersen","year":"2015","unstructured":"Jespersen S, Honge BL, Oliveira I, Medina C, da Silva Te D, Correira FG, et al. Cohort profile: the Bissau HIV cohort-a cohort of HIV-1, HIV-2 and co-infected patients. Int J Epidemiol. 2015;44(3):756\u201363.","journal-title":"Int J Epidemiol"},{"issue":"2","key":"259_CR3","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1093\/jac\/dky443","volume":"74","author":"N Ngo-Giang-Huong","year":"2019","unstructured":"Ngo-Giang-Huong N, Huynh THK, Dagnra AY, Toni TD, Maiga AI, Kania D, et al. Prevalence of pretreatment HIV drug resistance in West African and Southeast Asian countries. J Antimicrob Chemother. 2019;74(2):462\u20137.","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"259_CR4","doi-asserted-by":"publisher","first-page":"e0206406","DOI":"10.1371\/journal.pone.0206406","volume":"13","author":"S Wilhelmson","year":"2018","unstructured":"Wilhelmson S, Mansson F, Lopatko Lindman J, Biai A, Esbjornsson J, Norrgren H, et al. Prevalence of HIV-1 pretreatment drug resistance among treatment naive pregnant women in Bissau, Guinea Bissau. PLoS ONE. 2018;13(10):e0206406.","journal-title":"PLoS ONE"},{"key":"259_CR5","doi-asserted-by":"publisher","first-page":"20243","DOI":"10.7448\/IAS.18.1.20243","volume":"18","author":"S Jespersen","year":"2015","unstructured":"Jespersen S, Honge BL, Medina C, da Silva Te D, Correira FG, Laursen AL, et al. Lack of awareness of treatment failure among HIV-1-infected patients in Guinea-Bissau\u2014a retrospective cohort study. J Int AIDS Soc. 2015;18:20243.","journal-title":"J Int AIDS Soc."},{"key":"259_CR6","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12985-015-0273-9","volume":"12","author":"S Jespersen","year":"2015","unstructured":"Jespersen S, Tolstrup M, Honge BL, Medina C, Te Dda S, Ellermann-Eriksen S, et al. High level of HIV-1 drug resistance among patients with HIV-1 and HIV-1\/2 dual infections in Guinea-Bissau. Virol J. 2015;12:41.","journal-title":"Virol J."},{"issue":"3","key":"259_CR7","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1097\/QAI.0000000000001820","volume":"79","author":"S Jespersen","year":"2018","unstructured":"Jespersen S, H\u00f8nge BL, Krarup H, Medstrand P, S\u00f8rensen A, Medina C, da Silva T\u00e9 D, Correira FG, Erikstrup C, \u00d8stergaard L, Wejse C. Protease inhibitors or NNRTIs as first-line HIV-1 treatment in West Africa (PIONA): a randomized controlled trial. J Acquir Immune Defic Syndr. 2018;79(3):386\u201393.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"10","key":"259_CR8","doi-asserted-by":"publisher","first-page":"e003499","DOI":"10.1136\/bmjopen-2013-003499","volume":"3","author":"BL Honge","year":"2013","unstructured":"Honge BL, Jespersen S, Nordentoft PB, Medina C, da Silva D, da Silva ZJ, et al. Loss to follow-up occurs at all stages in the diagnostic and follow-up period among HIV-infected patients in Guinea-Bissau: a 7-year retrospective cohort study. BMJ Open. 2013;3(10):e003499.","journal-title":"BMJ Open"},{"issue":"1","key":"259_CR9","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1097\/QAI.0b013e3182a97b81","volume":"65","author":"BL Honge","year":"2014","unstructured":"Honge BL, Bjarnason Obinah MP, Jespersen S, Medina C, Te Dda S, da Silva ZJ, et al. Performance of 3 rapid tests for discrimination between HIV-1 and HIV-2 in Guinea-Bissau, West Africa. J Acquir Immune Defic Syndr. 2014;65(1):87\u201390.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"4","key":"259_CR10","doi-asserted-by":"publisher","first-page":"e214","DOI":"10.1016\/S2352-3018(19)30089-X","volume":"6","author":"J Esbjornsson","year":"2019","unstructured":"Esbjornsson J, Mansson F, Lindman J, Rowland-Jones SL, Jansson M, Medstrand P, et al. New insights are game-changers in HIV-2 disease management\u2014authors\u2019 reply. Lancet HIV. 2019;6(4):e214\u20135.","journal-title":"Lancet HIV."},{"key":"259_CR11","unstructured":"UNAIDS. http:\/\/www.unaids.org\/en\/regionscountries\/countries\/guinea-bissau."},{"issue":"4761","key":"259_CR12","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1126\/science.2425430","volume":"233","author":"F Clavel","year":"1986","unstructured":"Clavel F, Guetard D, Brun-Vezinet F, Chamaret S, Rey MA, Santos-Ferreira MO, et al. Isolation of a new human retrovirus from West African patients with AIDS. Science. 1986;233(4761):343\u20136.","journal-title":"Science"},{"issue":"14","key":"259_CR13","doi-asserted-by":"publisher","first-page":"8979","DOI":"10.1128\/JVI.79.14.8979-8990.2005","volume":"79","author":"KK Arien","year":"2005","unstructured":"Arien KK, Abraha A, Quinones-Mateu ME, Kestens L, Vanham G, Arts EJ. The replicative fitness of primary human immunodeficiency virus type 1 (HIV-1) group M, HIV-1 group O, and HIV-2 isolates. J Virol. 2005;79(14):8979\u201390.","journal-title":"J Virol"},{"issue":"8642","key":"259_CR14","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/S0140-6736(89)92281-2","volume":"1","author":"AG Poulsen","year":"1989","unstructured":"Poulsen AG, Kvinesdal B, Aaby P, Molbak K, Frederiksen K, Dias F, et al. Prevalence of and mortality from human immunodeficiency virus type 2 in Bissau, West Africa. Lancet. 1989;1(8642):827\u201331.","journal-title":"Lancet."},{"issue":"8","key":"259_CR15","first-page":"941","volume":"6","author":"AG Poulsen","year":"1993","unstructured":"Poulsen AG, Aaby P, Gottschau A, Kvinesdal BB, Dias F, Molbak K, et al. HIV-2 infection in Bissau, West Africa, 1987\u20131989: incidence, prevalences, and routes of transmission. J Acquir Immune Defic Syndr. 1993;6(8):941\u20138.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"13","key":"259_CR16","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1097\/00002030-199813000-00020","volume":"12","author":"O Larsen","year":"1998","unstructured":"Larsen O, da Silva Z, Sandstrom A, Andersen PK, Andersson S, Poulsen AG, et al. Declining HIV-2 prevalence and incidence among men in a community study from Guinea-Bissau. AIDS. 1998;12(13):1707\u201314.","journal-title":"AIDS."},{"issue":"10","key":"259_CR17","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1097\/QAD.0b013e328300a33d","volume":"22","author":"ZJ da Silva","year":"2008","unstructured":"da Silva ZJ, Oliveira I, Andersen A, Dias F, Rodrigues A, Holmgren B, et al. Changes in prevalence and incidence of HIV-1, HIV-2 and dual infections in urban areas of Bissau, Guinea-Bissau: is HIV-2 disappearing? AIDS. 2008;22(10):1195\u2013202.","journal-title":"AIDS."},{"issue":"9","key":"259_CR18","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1097\/QAD.0000000000001827","volume":"32","author":"JS Olesen","year":"2018","unstructured":"Olesen JS, Jespersen S, da Silva ZJ, Rodrigues A, Erikstrup C, Aaby P, et al. HIV-2 continues to decrease, whereas HIV-1 is stabilizing in Guinea-Bissau. AIDS. 2018;32(9):1193\u20138.","journal-title":"AIDS."},{"issue":"2","key":"259_CR19","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1080\/003655400750045286","volume":"32","author":"AG Poulsen","year":"2000","unstructured":"Poulsen AG, Aaby P, Jensen H, Dias F. Risk factors for HIV-2 seropositivity among older people in Guinea-Bissau. A search for the early history of HIV-2 infection. Scand J Infect Dis. 2000;32(2):169\u201375.","journal-title":"Scand J Infect Dis."},{"issue":"A","key":"259_CR20","first-page":"S69","volume":"13","author":"MFS van der Loeff","year":"1999","unstructured":"van der Loeff MFS, Aaby P. Towards a better understanding of the epidemiology of HIV-2. AIDS. 1999;13(A):S69\u201384.","journal-title":"AIDS."},{"issue":"9","key":"259_CR21","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1097\/01.aids.0000232239.05545.33","volume":"20","author":"J Pepin","year":"2006","unstructured":"Pepin J, Plamondon M, Alves AC, Beaudet M, Labbe AC. Parenteral transmission during excision and treatment of tuberculosis and trypanosomiasis may be responsible for the HIV-2 epidemic in Guinea-Bissau. AIDS. 2006;20(9):1303\u201311.","journal-title":"AIDS."},{"issue":"12","key":"259_CR22","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1097\/QAD.0b013e32832cedfb","volume":"23","author":"F Mansson","year":"2009","unstructured":"Mansson F, Biague A, da Silva ZJ, Dias F, Nilsson LA, Andersson S, et al. Prevalence and incidence of HIV-1 and HIV-2 before, during and after a civil war in an occupational cohort in Guinea-Bissau, West Africa. AIDS. 2009;23(12):1575\u201382.","journal-title":"AIDS."},{"key":"259_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(18)30254-6","author":"J Esbjornsson","year":"2018","unstructured":"Esbjornsson J, Mansson F, Kvist A, Silva ZJ, Andersson S, Fenyo EM, et al. Long-term follow-up of HIV-2-related AIDS and mortality in Guinea-Bissau: a prospective open cohort study. Lancet HIV. 2018. https:\/\/doi.org\/10.1016\/S2352-3018(18)30254-6.","journal-title":"Lancet HIV."},{"issue":"3","key":"259_CR24","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1056\/NEJMoa1113244","volume":"367","author":"J Esbjornsson","year":"2012","unstructured":"Esbjornsson J, Mansson F, Kvist A, Isberg PE, Nowroozalizadeh S, Biague AJ, et al. Inhibition of HIV-1 disease progression by contemporaneous HIV-2 infection. N Engl J Med. 2012;367(3):224\u201332.","journal-title":"N Engl J Med"},{"issue":"4","key":"259_CR25","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1097\/QAD.0000000000000142","volume":"28","author":"J Esbjornsson","year":"2014","unstructured":"Esbjornsson J, Mansson F, Kvist A, Isberg PE, Nowroozalizadeh S, Biague AJ, et al. Effect of HIV-2 infection on HIV-1 disease progression and mortality. AIDS. 2014;28(4):614\u20135.","journal-title":"AIDS."},{"issue":"7","key":"259_CR26","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1097\/QAD.0000000000000101","volume":"28","author":"J Esbjornsson","year":"2014","unstructured":"Esbjornsson J, Mansson F, Kvist A, Isberg PE, Biague AJ, da Silva ZJ, et al. Increased survival among HIV-1 and HIV-2 dual-infected individuals compared to HIV-1 single-infected individuals. Aids. 2014;28(7):949\u201357.","journal-title":"Aids."},{"issue":"9","key":"259_CR27","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1089\/aid.2015.0073","volume":"31","author":"AA Palm","year":"2015","unstructured":"Palm AA, Esbjornsson J, Mansson F, Biague A, da Silva ZJ, Norrgren H, et al. Cocirculation of several similar but unique HIV-1 recombinant forms in Guinea-Bissau revealed by near full-length genomic sequencing. AIDS Res Hum Retroviruses. 2015;31(9):938\u201345.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"5","key":"259_CR28","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1093\/infdis\/jit416","volume":"209","author":"AA Palm","year":"2014","unstructured":"Palm AA, Esbjornsson J, Mansson F, Kvist A, Isberg PE, Biague A, et al. Faster progression to AIDS and AIDS-related death among seroincident individuals infected with recombinant HIV-1 A3\/CRF02_AG compared with sub-subtype A3. J Infect Dis. 2014;209(5):721\u20138.","journal-title":"J Infect Dis"},{"issue":"2","key":"259_CR29","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1128\/JVI.06315-11","volume":"86","author":"G Ozkaya Sahin","year":"2012","unstructured":"Ozkaya Sahin G, Holmgren B, da Silva Z, Nielsen J, Nowroozalizadeh S, Esbjornsson J, et al. Potent intratype neutralizing activity distinguishes human immunodeficiency virus type 2 (HIV-2) from HIV-1. J Virol. 2012;86(2):961\u201371.","journal-title":"J Virol"},{"issue":"8","key":"259_CR30","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1111\/j.1600-0463.2011.02763.x","volume":"119","author":"L Vinner","year":"2011","unstructured":"Vinner L, Holmgren B, Jensen KJ, Esbjornsson J, Borggren M, Hentze JL, et al. Sequence analysis of HIV-1 isolates from Guinea-Bissau: selection of vaccine epitopes relevant in both West African and European countries. APMIS. 2011;119(8):487\u201397.","journal-title":"APMIS."},{"issue":"2","key":"259_CR31","doi-asserted-by":"publisher","first-page":"e17025","DOI":"10.1371\/journal.pone.0017025","volume":"6","author":"J Esbjornsson","year":"2011","unstructured":"Esbjornsson J, Mild M, Mansson F, Norrgren H, Medstrand P. HIV-1 molecular epidemiology in Guinea-Bissau, West Africa: origin, demography and migrations. PLoS ONE. 2011;6(2):e17025.","journal-title":"PLoS ONE"},{"key":"259_CR32","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/1742-4690-7-23","volume":"7","author":"J Esbjornsson","year":"2010","unstructured":"Esbjornsson J, Mansson F, Martinez-Arias W, Vincic E, Biague AJ, da Silva ZJ, et al. Frequent CXCR4 tropism of HIV-1 subtype A and CRF02_AG during late-stage disease\u2013indication of an evolving epidemic in West Africa. Retrovirology. 2010;7:23.","journal-title":"Retrovirology."},{"issue":"1","key":"259_CR33","doi-asserted-by":"publisher","first-page":"e01245-18","DOI":"10.1128\/mBio.01245-18","volume":"10","author":"AA Palm","year":"2019","unstructured":"Palm AA, Lemey P, Jansson M, M\u00e5nsson F, Kvist A, Szojka Z, et al. Low postseroconversion CD4+ T-cell level is associated with faster disease progression and higher viral evolutionary rate in HIV-2 infection. mBio. 2019;10(1):e01245-18.","journal-title":"mBio."},{"issue":"11","key":"259_CR34","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1093\/infdis\/jiz001","volume":"219","author":"I Karlsson","year":"2019","unstructured":"Karlsson I, Tingstedt JL, Sahin GO, Hansen M, Szojka Z, Buggert M, et al. Cross-reactive antibodies with the capacity to mediate hiv-1 envelope glycoprotein-targeted antibody-dependent cellular cytotoxicity identified in HIV-2-Infected individuals. J Infect Dis. 2019;219(11):1749\u201354.","journal-title":"J Infect Dis"},{"issue":"16","key":"259_CR35","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1097\/QAD.0000000000001223","volume":"30","author":"M Buggert","year":"2016","unstructured":"Buggert M, Frederiksen J, Lund O, Betts MR, Biague A, Nielsen M, et al. CD4\u2009+\u2009T cells with an activated and exhausted phenotype distinguish immunodeficiency during aviremic HIV-2 infection. AIDS. 2016;30(16):2415\u201326.","journal-title":"AIDS."},{"issue":"11","key":"259_CR36","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1097\/QAD.0000000000001147","volume":"30","author":"SM Bachle","year":"2016","unstructured":"Bachle SM, Malone DF, Buggert M, Karlsson AC, Isberg PE, Biague AJ, et al. Elevated levels of invariant natural killer T-cell and natural killer cell activation correlate with disease progression in HIV-1 and HIV-2 infections. AIDS. 2016;30(11):1713\u201322.","journal-title":"AIDS."},{"issue":"3","key":"259_CR37","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1089\/aid.2012.0219","volume":"29","author":"G Ozkaya Sahin","year":"2013","unstructured":"Ozkaya Sahin G, Mansson F, Palm AA, Vincic E, da Silva Z, Medstrand P, et al. Frequent intratype neutralization by plasma immunoglobulin a identified in HIV type 2 infection. AIDS Res Hum Retroviruses. 2013;29(3):470\u20138.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"8","key":"259_CR38","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1086\/651430","volume":"201","author":"S Nowroozalizadeh","year":"2010","unstructured":"Nowroozalizadeh S, Mansson F, da Silva Z, Repits J, Dabo B, Pereira C, et al. Microbial translocation correlates with the severity of both HIV-1 and HIV-2 infections. J Infect Dis. 2010;201(8):1150\u20134.","journal-title":"J Infect Dis"},{"key":"259_CR39","first-page":"128","volume":"32","author":"C Wejse","year":"2015","unstructured":"Wejse C, Patsche CB, Kuhle A, Bamba FJ, Mendes MS, Lemvik G, et al. Impact of HIV-1, HIV-2, and HIV-1\u2009+\u20092 dual infection on the outcome of tuberculosis. IJID. 2015;32:128\u201334.","journal-title":"IJID."},{"key":"259_CR40","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/1742-4690-7-50","volume":"7","author":"C van Tienen","year":"2010","unstructured":"van Tienen C, van der Loeff MF, Peterson I, Cotten M, Holmgren B, Andersson S, et al. HTLV-1 in rural Guinea-Bissau: prevalence, incidence and a continued association with HIV between 1990 and 2007. Retrovirology. 2010;7:50.","journal-title":"Retrovirology."},{"issue":"4","key":"259_CR41","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1097\/00042560-199508000-00014","volume":"9","author":"H Norrgren","year":"1995","unstructured":"Norrgren H, Andersson S, Naucler A, Dias F, Johansson I, Biberfeld G. HIV-1, HIV-2, HTLV-I\/II and Treponema pallidum infections: incidence, prevalence, and HIV-2-associated mortality in an occupational cohort in Guinea-Bissau. J Acqui Immune Defic Syndr Hum Retrovirol. 1995;9(4):422\u20138.","journal-title":"J Acqui Immune Defic Syndr Hum Retrovirol."},{"key":"259_CR42","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.actatropica.2019.02.015","volume":"192","author":"MM Jensen","year":"2019","unstructured":"Jensen MM, Olesen JS, Kjerulff B, Byberg S, da Silva ZJ, Rodrigues A, et al. HTLV prevalence is no longer following the decreasing HIV prevalence\u201420\u00a0years of retroviral surveillance in Guinea-Bissau, West Africa. Acta Tropica. 2019;192:144\u201350.","journal-title":"Acta Tropica."},{"issue":"6","key":"259_CR43","doi-asserted-by":"publisher","first-page":"e99971","DOI":"10.1371\/journal.pone.0099971","volume":"9","author":"BL H\u00f8nge","year":"2014","unstructured":"H\u00f8nge BL, Jespersen S, Medina C, Te Dda S, da Silva ZJ, Lewin S, et al. Hepatitis B and delta virus are prevalent but often subclinical co-infections among HIV infected patients in Guinea-Bissau, West Africa: a cross-sectional study. PLoS ONE. 2014;9(6):e99971.","journal-title":"PLoS ONE"},{"key":"259_CR44","first-page":"35","volume":"28","author":"BL Honge","year":"2014","unstructured":"Honge BL, Jespersen S, Medina C, da Silva Te D, da Silva ZJ, Lewin SR, et al. Hepatitis C prevalence among HIV-infected patients in Guinea-Bissau: a descriptive cross-sectional study. IJID. 2014;28:35\u201340.","journal-title":"IJID"},{"issue":"6","key":"259_CR45","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1136\/sti.2007.025353","volume":"83","author":"F Mansson","year":"2007","unstructured":"Mansson F, Alves A, Silva ZJ, Dias F, Andersson S, Biberfeld G, et al. Trends of HIV-1 and HIV-2 prevalence among pregnant women in Guinea-Bissau, West Africa: possible effect of the civil war 1998 1999. Sex Transm Infect. 2007;83(6):463\u20137.","journal-title":"Sex Transm Infect."},{"issue":"9","key":"259_CR46","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1258\/ijsa.2010.009584","volume":"21","author":"F Mansson","year":"2010","unstructured":"Mansson F, Camara C, Biai A, Monteiro M, da Silva ZJ, Dias F, et al. High prevalence of HIV-1, HIV-2 and other sexually transmitted infections among women attending two sexual health clinics in Bissau, Guinea-Bissau. West Africa. Int J STD AIDS. 2010;21(9):631\u20135.","journal-title":"West Africa. Int J STD AIDS."},{"issue":"5","key":"259_CR47","doi-asserted-by":"publisher","first-page":"301","DOI":"10.3855\/jidc.570","volume":"4","author":"A Biague","year":"2010","unstructured":"Biague A, Mansson F, da Silva Z, Dias F, Nantote Q, Costa J, et al. High sexual risk taking and diverging trends of HIV-1 and HIV-2 in the military of Guinea Bissau. J Infect Dev Ctries. 2010;4(5):301\u20138.","journal-title":"J Infect Dev Ctries."},{"issue":"2","key":"259_CR48","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s15010-016-0949-0","volume":"45","author":"PB Nordentoft","year":"2017","unstructured":"Nordentoft PB, Engell-Sorensen T, Jespersen S, Correia FG, Medina C, da Silva Te D, et al. Assessing factors for loss to follow-up of HIV infected patients in Guinea-Bissau. Infection. 2017;45(2):187\u201397.","journal-title":"Infection"},{"issue":"4","key":"259_CR49","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1177\/2325957415599211","volume":"15","author":"C Dyrehave","year":"2016","unstructured":"Dyrehave C, Rasmussen DN, H\u00f8nge BL, Jespersen S, Correia FG, Medina C, et al. Nonadherence is associated with lack of HIV-related knowledge: a cross-sectional study among HIV-infected individuals in Guinea-Bissau. J Int Assoc Provid AIDS Care. 2016;15(4):350\u20138.","journal-title":"J Int Assoc Provid AIDS Care."},{"issue":"1","key":"259_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2989\/16085906.2013.815405","volume":"12","author":"DN Rasmussen","year":"2013","unstructured":"Rasmussen DN, Te DdS, Roedkjaer L, Oliveira I, Medinca C, Barfod T, et al. Barriers and facilitators to antiretroviral therapy adherence among patients with HIV in Bissau, Guinea-Bissau: a qualitative study. Afr J AIDS Res. 2013;12(1):1\u20138.","journal-title":"Afr J AIDS Res."},{"key":"259_CR51","unstructured":"WHO. Monitoring response to ART and the diagnosis of treatment failure. Consolidated ARV guidelines. 2013. http:\/\/www.who.int\/hiv\/pub\/guidelines\/arv2013\/art\/artmonitoring\/en\/."},{"key":"259_CR52","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/1742-4690-7-46","volume":"7","author":"MF van der Loeff","year":"2010","unstructured":"van der Loeff MF, Larke N, Kaye S, Berry N, Ariyoshi K, Alabi A, et al. Undetectable plasma viral load predicts normal survival in HIV-2-infected people in a West African village. Retrovirology. 2010;7:46.","journal-title":"Retrovirology."},{"issue":"7","key":"259_CR53","doi-asserted-by":"publisher","first-page":"e25008","DOI":"10.1002\/jia2.25008","volume":"20","author":"T Peter","year":"2017","unstructured":"Peter T, Zeh C, Katz Z, Elbireer A, Alemayehu B, Vojnov L, et al. Scaling up HIV viral load\u2014lessons from the large-scale implementation of HIV early infant diagnosis and CD4 testing. J Int AIDS Soc. 2017;20(7):e25008.","journal-title":"J Int AIDS Soc."},{"issue":"47","key":"259_CR54","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.15585\/mmwr.mm6547a2","volume":"65","author":"S Lecher","year":"2016","unstructured":"Lecher S, Williams J, Fonjungo PN, Kim AA, Ellenberger D, Zhang G, et al. Progress with scale-up of HIV viral load monitoring\u2014seven Sub-Saharan African Countries, January 2015\u2013June 2016. MMWR Morb Mortal Wkly Rep. 2016;65(47):1332\u20135.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"7","key":"259_CR55","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1093\/jac\/dkx090","volume":"72","author":"S Requena","year":"2017","unstructured":"Requena S, Trevino A, Cabezas T, Garcia-Delgado R, Amengual MJ, Lozano AB, et al. Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response. J Antimicrob Chemother. 2017;72(7):2083\u20138.","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"259_CR56","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1089\/088922204322996590","volume":"20","author":"E Poveda","year":"2004","unstructured":"Poveda E, Rodes B, Toro C, Soriano V. Are fusion inhibitors active against all HIV variants? AIDS Res Hum Retroviruses. 2004;20(3):347\u20138.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"5","key":"259_CR57","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1093\/jac\/dkn335","volume":"62","author":"B Roquebert","year":"2008","unstructured":"Roquebert B, Damond F, Collin G, Matheron S, Peytavin G, Benard A, et al. HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro. J Antimicrob Chemother. 2008;62(5):914\u201320.","journal-title":"J Antimicrob Chemother"},{"issue":"17","key":"259_CR58","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1097\/QAD.0b013e32833f9e36","volume":"24","author":"C Charpentier","year":"2010","unstructured":"Charpentier C, Larrouy L, Collin G, Damond F, Matheron S, Chene G, et al. In-vitro phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitor S\/GSK1349572. AIDS. 2010;24(17):2753\u20135.","journal-title":"AIDS."},{"key":"259_CR59","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12977-015-0146-8","volume":"12","author":"RA Smith","year":"2015","unstructured":"Smith RA, Raugi DN, Pan C, Sow PS, Seydi M, Mullins JI, et al. In vitro activity of dolutegravir against wild-type and integrase inhibitor-resistant HIV-2. Retrovirology. 2015;12:10.","journal-title":"Retrovirology."},{"key":"259_CR60","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jcv.2015.01.001","volume":"64","author":"A Trevino","year":"2015","unstructured":"Trevino A, Cabezas T, Lozano AB, Garcia-Delgado R, Force L, Fernandez-Montero JM, et al. Dolutegravir for the treatment of HIV-2 infection. J Clin Virol. 2015;64:12\u20135.","journal-title":"J Clin Virol."},{"issue":"1","key":"259_CR61","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/135965350400900115","volume":"9","author":"M Witvrouw","year":"2004","unstructured":"Witvrouw M, Pannecouque C, Switzer WM, Folks TM, De Clercq E, Heneine W. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antivir Ther. 2004;9(1):57\u201365.","journal-title":"Antivir Ther."},{"issue":"4","key":"259_CR62","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1128\/AAC.01284-07","volume":"52","author":"D Desbois","year":"2008","unstructured":"Desbois D, Roquebert B, Peytavin G, Damond F, Collin G, Benard A, et al. In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors. Antimicrob Agents Chemother. 2008;52(4):1545\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"259_CR63","unstructured":"WHO. Update of recommendations on first- and second-line antiretroviral regimens 2019. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/325892\/WHO-CDS-HIV-19.15-eng.pdf?ua=1."},{"issue":"7","key":"259_CR64","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1093\/jac\/dkr164","volume":"66","author":"A Trevino","year":"2011","unstructured":"Trevino A, de Mendoza C, Caballero E, Rodriguez C, Parra P, Benito R, et al. Drug resistance mutations in patients infected with HIV-2 living in Spain. J Antimicrob Chemother. 2011;66(7):1484\u20138.","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"259_CR65","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1086\/599107","volume":"48","author":"S Jallow","year":"2009","unstructured":"Jallow S, Vincent T, Leligdowicz A, De Silva T, Van Tienen C, Alabi A, et al. Presence of a multidrug-resistance mutation in an HIV-2 variant infecting a treatment-naive individual in Caio Guinea Bissau. Clin Infect Dis. 2009;48(12):1790\u20133.","journal-title":"Clin Infect Dis."},{"issue":"7","key":"259_CR66","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1128\/JCM.01654-08","volume":"47","author":"S Jallow","year":"2009","unstructured":"Jallow S, Alabi A, Sarge-Njie R, Peterson K, Whittle H, Corrah T, et al. Virological response to highly active antiretroviral therapy in patients infected with human immunodeficiency virus type 2 (HIV-2) and in patients dually infected with HIV-1 and HIV-2 in the Gambia and emergence of drug-resistant variants. J Clin Microbiol. 2009;47(7):2200\u20138.","journal-title":"J Clin Microbiol"},{"issue":"8","key":"259_CR67","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1097\/QAD.0000000000000244","volume":"28","author":"C Charpentier","year":"2014","unstructured":"Charpentier C, Eholie S, Anglaret X, Bertine M, Rouzioux C, Avettand-Fenoel V, et al. Genotypic resistance profiles of HIV-2-treated patients in West Africa. Aids. 2014;28(8):1161\u20139.","journal-title":"Aids."},{"issue":"6","key":"259_CR68","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.1128\/AAC.00405-13","volume":"57","author":"DN Raugi","year":"2013","unstructured":"Raugi DN, Smith RA, Ba S, Toure M, Traore F, Sall F, et al. Complex patterns of protease inhibitor resistance among antiretroviral treatment-experienced HIV-2 patients from Senegal: implications for second-line therapy. Antimicrob Agents Chemother. 2013;57(6):2751\u201360.","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"259_CR69","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1097\/QAD.0000000000001107","volume":"30","author":"F Duarte","year":"2016","unstructured":"Duarte F, Miranda AC, Peres S, Diogo I, Goncalves F, Carvalho AP, et al. Transmitted drug resistance in drug-naive HIV-2 infected patients. AIDS. 2016;30(10):1687\u20138.","journal-title":"AIDS."},{"issue":"8","key":"259_CR70","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1093\/cid\/civ572","volume":"61","author":"C Charpentier","year":"2015","unstructured":"Charpentier C, Camacho R, Ruelle J, Eberle J, Gurtler L, Pironti A, et al. HIV-2EU-supporting standardized HIV-2 drug-resistance interpretation in Europe: an update. Clin Infect Dis. 2015;61(8):1346\u20137.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"259_CR71","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1097\/QAD.0b013e328133f285","volume":"21","author":"M May","year":"2007","unstructured":"May M, Sterne JA, Sabin C, Costagliola D, Justice AC, Thiebaut R, et al. Prognosis of HIV-1-infected patients up to 5\u00a0years after initiation of HAART: collaborative analysis of prospective studies. AIDS. 2007;21(9):1185\u201397.","journal-title":"AIDS."},{"issue":"3","key":"259_CR72","doi-asserted-by":"publisher","first-page":"e100","DOI":"10.1097\/QAI.0000000000000645","volume":"69","author":"JE Hernandez-Avila","year":"2015","unstructured":"Hernandez-Avila JE, Palacio-Mejia LS, Hernandez-Romieu A, Bautista-Arredondo S, Sepulveda Amor J, Hernandez-Avila M. Implementation and operational research: effect of universal access to antiretroviral therapy on HIV\/AIDS mortality in Mexico 1990\u20132011. J Acquir Immune Defic Syndr. 2015;69(3):e100\u20138.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"3","key":"259_CR73","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/QAD.0000000000001335","volume":"31","author":"A Gueler","year":"2017","unstructured":"Gueler A, Moser A, Calmy A, Gunthard HF, Bernasconi E, Furrer H, et al. Life expectancy in HIV-positive persons in Switzerland: matched comparison with general population. AIDS. 2017;31(3):427\u201336.","journal-title":"AIDS."},{"issue":"4","key":"259_CR74","doi-asserted-by":"publisher","first-page":"209","DOI":"10.7326\/0003-4819-155-4-201108160-00358","volume":"155","author":"EJ Mills","year":"2011","unstructured":"Mills EJ, Bakanda C, Birungi J, Chan K, Ford N, Cooper CL, et al. Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda. Ann Intern Med. 2011;155(4):209\u201316.","journal-title":"Ann Intern Med"},{"issue":"4","key":"259_CR75","doi-asserted-by":"publisher","first-page":"e1001418","DOI":"10.1371\/journal.pmed.1001418","volume":"10","author":"LF Johnson","year":"2013","unstructured":"Johnson LF, Mossong J, Dorrington RE, Schomaker M, Hoffmann CJ, Keiser O, et al. Life expectancies of South African adults starting antiretroviral treatment: collaborative analysis of cohort studies. PLoS Med. 2013;10(4):e1001418.","journal-title":"PLoS Med."},{"issue":"3","key":"259_CR76","doi-asserted-by":"publisher","first-page":"e169","DOI":"10.1016\/S2214-109X(14)70364-X","volume":"3","author":"S Nsanzimana","year":"2015","unstructured":"Nsanzimana S, Remera E, Kanters S, Chan K, Forrest JI, Ford N, et al. Life expectancy among HIV-positive patients in Rwanda: a retrospective observational cohort study. Lancet Global Health. 2015;3(3):e169\u201377.","journal-title":"Lancet Global Health."},{"issue":"3","key":"259_CR77","first-page":"487","volume":"30","author":"G Asiki","year":"2016","unstructured":"Asiki G, Reniers G, Newton R, Baisley K, Nakiyingi-Miiro J, Slaymaker E, et al. Adult life expectancy trends in the era of antiretroviral treatment in rural Uganda (1991\u20132012). AIDS. 2016;30(3):487\u201393.","journal-title":"AIDS."},{"issue":"15","key":"259_CR78","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1097\/QAD.0b013e32830007cd","volume":"22","author":"SD Lawn","year":"2008","unstructured":"Lawn SD, Harries AD, Anglaret X, Myer L, Wood R. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS. 2008;22(15):1897\u2013908.","journal-title":"AIDS."},{"key":"259_CR79","doi-asserted-by":"publisher","first-page":"40","DOI":"10.11604\/pamj.2016.25.40.8329","volume":"25","author":"BL Honge","year":"2016","unstructured":"Honge BL, Jespersen S, Aunsborg J, Mendes DV, Medina C, da Silva Te D, et al. High prevalence and excess mortality of late presenters among HIV-1, HIV-2 and HIV-1\/2 dually infected patients in Guinea-Bissau \u2014a cohort study from West Africa. Pan Afr Med J. 2016;25:40.","journal-title":"Pan Afr Med J."},{"issue":"2","key":"259_CR80","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/tmi.12646","volume":"21","author":"S Jespersen","year":"2016","unstructured":"Jespersen S, Honge BL, Esbjornsson J, Medina C, da Silva Te D, Correira FG, et al. Differential effects of sex in a West African cohort of HIV-1, HIV-2 and HIV-1\/2 dually infected patients: men are worse off. Trop Med Int Health. 2016;21(2):253\u201362.","journal-title":"Trop Med Int Health."},{"issue":"5","key":"259_CR81","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1097\/COH.0000000000000299","volume":"11","author":"B Tchounga","year":"2016","unstructured":"Tchounga B, Ekouevi DK, Balestre E, Dabis F. Mortality and survival patterns of people living with HIV-2. Current Opin HIV AIDS. 2016;11(5):537\u201344.","journal-title":"Current Opin HIV AIDS."},{"key":"259_CR82","unstructured":"UNAIDS. 90\u201390\u201390 \u2014an ambitious treatment target to help end the AIDS epidemic 2017. www.unaids.org\/en\/resources\/documents\/2017\/90-90-90."},{"issue":"3","key":"259_CR83","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S1473-3099(09)70328-7","volume":"10","author":"RE Barth","year":"2010","unstructured":"Barth RE, van der Loeff MF, Schuurman R, Hoepelman AI, Wensing AM. Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. Lancet Infect Dis. 2010;10(3):155\u201366.","journal-title":"Lancet Infect Dis."},{"key":"259_CR84","unstructured":"UNAIDS. Undetectable untransmittable public health and hiv viral load suppression 2018. http:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/undetectable-untransmittable_en.pdf."},{"issue":"6","key":"259_CR85","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/hiv.12606","volume":"19","author":"BL Honge","year":"2018","unstructured":"Honge BL, Jespersen S, Medina C, Te DS, da Silva ZJ, Christiansen M, et al. The challenge of discriminating between HIV-1, HIV-2 and HIV-1\/2 dual infections. HIV Med. 2018;19(6):403\u201310.","journal-title":"HIV Med."},{"key":"259_CR86","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jviromet.2019.03.005","volume":"268","author":"J Lindman","year":"2019","unstructured":"Lindman J, Honge BL, Kjerulff B, Medina C, da Silva ZJ, Erikstrup C, et al. Performance of Bio-Rad HIV-1\/2 Confirmatory Assay in HIV-1, HIV-2 and HIV-1\/2 dually reactive patients\u2013comparison with INNO-LIA and immunocomb discriminatory assays. J Virol Methods. 2019;268:42\u20137.","journal-title":"J Virol Methods"},{"issue":"5","key":"259_CR87","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1097\/QAI.0000000000001960","volume":"80","author":"ET Montgomery","year":"2019","unstructured":"Montgomery ET, Atujuna M, Krogstad E, Hartmann M, Ndwayana S, O\u2019Rourke S, et al. The invisible product: preferences for sustained-release, long-acting pre-exposure prophylaxis to hiv among south african youth. J Acquir Immune Defic Syndr. 2019;80(5):542\u201350.","journal-title":"J Acquir Immune Defic Syndr"}],"container-title":["AIDS Research and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-020-0259-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12981-020-0259-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-020-0259-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T08:37:57Z","timestamp":1665736677000},"score":1,"resource":{"primary":{"URL":"https:\/\/aidsrestherapy.biomedcentral.com\/articles\/10.1186\/s12981-020-0259-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,4]]},"references-count":87,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["259"],"URL":"https:\/\/doi.org\/10.1186\/s12981-020-0259-6","relation":{},"ISSN":["1742-6405"],"issn-type":[{"value":"1742-6405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,4]]},"assertion":[{"value":"16 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3"}}